The Drug Induced Immune Hemolytic Anemia Market is poised to value at a CAGR of over 8% during the forecast period 2022 to 2028. Drug-induced immune hemolytic anemia (DIIHA) is rare and often requires a specialized laboratory to provide optimal serological tests to confirm the diagnosis. Hypotheses about the mechanisms thought to be related to […]
